Pregnancy with Mixed Connective Tissue Disease: exploration of factors influencing live birth outcomes-Reference-Cited by-同舟云学术

Pregnancy with Mixed Connective Tissue Disease: exploration of factors influencing live birth outcomes

Published:2024-03-14 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Yoshida Tsukasa¹,Takeda Jun¹,Ishii Sumire¹,Matsushita Masakazu²,Tamura Naoto²,Itakura Atsuo¹

Affiliation:

1. Juntendo University Faculty of Medicine

2. Juntendo University School of Medicine

Abstract

Abstract Background Mixed connective tissue disease (MCTD) predominantly affects women in their reproductive age (30–40 years). This study is aimed to analyze a case series of MCTD-complicated pregnancies. Methods The study design utilized a combined case-series and case-control approach. Pregnant women with MCTD were included and categorized into two groups: the live-birth group and the non-live birth group (encompassing miscarriages < 12 weeks and stillbirths ≥ 12 weeks). Primary outcomes included delivery outcomes and factors associated with live births. Results A total of 57 pregnancies from 34 mothers (median age: 33.0 years) were included. Regarding delivery outcomes, the rates for live birth, miscarriage, and stillbirth were 64.9%, 29.8%, and 5.3%, respectively. Additionally, the rates of preterm delivery, fetal growth restriction (FGR), and small-for-gestational-age (SGA) were 18.9%, 18.9%, and 27.0%, correspondingly. Regarding factors associated with live births, the live birth group demonstrated a higher prevalence and lower steroid dose usage compared to the non-live birth group (62.2% vs. 30.0%, p = 0.02; median dose: 7 mg vs. 10 mg, p = 0.03). Conclusions MCTD during pregnancy was associated with increased risks of miscarriage, stillbirth, preterm delivery, FGR, and SGA. Notably, low-dose steroid therapy has been identified as a contributing factor to successful live births.

Publisher

Research Square Platform LLC

Reference24 articles.

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148–59. http://dx.doi.org/10.1016/0002-9343(72)90064-2.

2. Gunnarsson R, Andreassen AK, Molberg Ø, Lexberg ÅS, Time K, Dhainaut ASS et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology. 2013;52(7):1208–13. http://dx.doi.org/10.1093/rheumatology/kes430.

3. Asherson RA, Cervera R. Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol. 2007;32(2):153–8. http://dx.doi.org/10.1007/s12016-007-0012-0.

4. Bonnin M, Mercier FJ, Sitbon O, Roger-Christoph S, Jaïs X, Humbert M et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133–7; discussion 5A-6A. http://dx.doi.org/10.1097/00000542-200506000-00012.

5. Izmirly PM, Halushka MK, Rosenberg AZ, Whelton S, Rais-Bahrami K, Nath DS et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmun Rev. 2017;16(9):980–3. http://dx.doi.org/10.1016/j.autrev.2017.07.013.